Table D-4. Clinician administered PTSD scales

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Akuchekian et al., 20041 | CAPSMean (SD)G1 Pre-tx: 50.70 (7.7)G1 Post-tx: 32.75 (8.2)G2 Pre-tx: 48.9 (9.13)G2 Post-tx: 46.62 (8.8)G1 vs. G2, p=0.00 (based on t-test) | NR | NR | NR |
| Asukai et al., 20102 | CAPSAdjusted Mean (SE)G1 Pre-tx:84.58 (7.78)G1 Post-tx: 43.76 (8.43)G2 Pre-tx:84.33 (7.78)G2 Post-tx: 84.81 (7.96)At post: G1 vs. G2= p<0.01(based on t-test) | NR | NR | NR |
| Bartzokis et al., 20053 | CAPSUnadjusted Change from baseline (SD)G1: -14.3 (16.7)G2: -4.6 (13.2) G1 vs. G2, p<0.05 | NR | NR | NR |
| Basoglu et al., 20074 | CAPSMean (SD)G1 Pre-tx: 63.1 (10.1)G1 Week 4: 38.7 (18.7)G1 Week 8:30.2 (20.3) G2 Pre-tx: 62.3 (14.5)G2 Week 4: 54.5 (16.9)G2 Week 8: 49.1 (20.3)G1 vs. G2 at Week 4, p<0.01G1 vs. G2 at Week 8, p<0.01 | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Becker et al., 20075 | CAPSWithin Group Mean Change (SD)(Baseline-Endpoint)G1: 12.33 (24.12) G2: 16.99 (11.26) Group effect , p<0.01 | NR | NR | NR |
| Blanchard et al., 20036 | CAPSMean (SD)G1 Pre-tx: 68.2 (22.7)G1 Post-tx: 23.7 (26.2)G2 Pre-tx: 65.0 (25.9)G2 Post-tx:40.1 (25.7)G3 Baseline: 65.8 (26.6)G3 Post-tx: 54.0 (25.9)Group X Time at post-tx, p<0.001G1 vs. G2, p=0.002G1 vs. G3, p<0.001G2 vs. G3, p=0.012Including DropoutsGroup X Time at post-tx, p<0.001G1 vs. G2, p=0.013G1 vs. G3, p<0.001G2 vs. G3, p=0.052Group X Time, 3 mth FUp=0.048G1 continued to have lower scores than G2, p=0.003Decreases from post-tx to the 3 mth fu, NS | NR | NR | NR |
| Boden et al., 20127 | NR | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Brady et al., 20008 | CAPS-2Mean change (SEM)G1: -33.0 (2.8)G2: -23.2 (2.9)Difference Between Mean Change (95% CI): 9.8 (1.8 to 17.7), p=0.02 | NR | NR | NR |
| Brady et al., 20059 | CAPSANCOVAF (2, 68) = 2.68, p=0.08 | NR | NR | NR |
| Bryant et al., 200310 | CAPS-IntensityMean (SD)G1 Pre-tx: 32.50 (8.71)G1 Post-tx: 19.15 (11.15)G1 6 mth FU: -20.70 (12.00)G2 Pre-tx: 32.70 (7.51)G2 Post-tx: 15.90 (13.36)G2 6 mth FU: 15.70 (14.79)G3 Pre-tx: 32.83 (8.01)G3 Post-tx: 28.00 (15.31)G3 6 mth FU: 30.28 (12.89)Post-tx, p<0.01 (main effects)FU, p<0.05 (main effects) | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Bryant et al., 200310 cont’d | CAPS-Frequency (CAPS-F)Mean (SD)G1 Pre-tx: 36.80 (9.82)G2 Post-tx: 20.55 (12.73)G1 6 mth FU: 23.25 (12.90)G2 Pre-tx: 36.00 (8.69)G2 Post-tx:17.20 (15.62)G2 6 mth FU: 17.00 (15.22)G3 Pre-tx: 38.33 (9.64)G3 Post-tx: 30.00 (16.42)G3 6 mth FU: 32.44 (13.57)Post-tx, p<0.01 (main effects)FU, p<0.05 (main effects) |  |  |  |
| Bryant et al., 200811 | CAPSMean (SD)G1 Pre-tx: 73.29 (18.82)G1 Post-tx: 55.50 (33.83)G1 6 mth FU: 59.94 (32.36)G2 Pre-tx: 76.79 (15.53)G2 Post-tx: 55.96 (24.56)G2 6 mth FU: 59.32 (29.62)G3 Pre-tx: 76.06 (19.19)G3 Post-tx: 55.39 (37.45)G3 6 mth FU: 56.39 (35.87)G4 Pre-tx: 71.35 (17.28)G4 Post-tx: 29.86 (27.11)G4 6 mth FU: 32.86 (27.44)Post-tx, p<0.01 (main effect)6 mth FU, p<0.005 (main effect) | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Butterfield et al., 200112  | NR | NR | SIP Mean (SD)G1 Pre-tx: 39.7 (9.7)G1 Post-tx: 19.2 (8.7)G2 Pre-tx: 45.9 (8.2)G2 Post-tx: 17.0 (17.5) | TOP-8Mean (SD)G1 Pre-tx: 19.3 (4.2)G1 Post-tx: 12.6 (6.4)G2Baseline: 21.8 (3.3)G2 Post-tx: 10.5 (8.7)SPRINT - Mean (SD)G1 Pre-tx: 31.5 (5.7)G2 Post-tx: 17.9 (7.8)G2 Pre-tx: 34.8 (2.1)G2 Post-tx: 20.5 (11.1) |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Carlson et al., 199813  | CAPS - FrequencyMean (SD)G1 Pre-tx: 2.5 (0.5)G1 3 mth FU: 0.7 (0.6)G2 Pre-tx: 2.6 (0.5)G2 3 mth FU: 2.0 (0.7)G3 Pre-tx: 2.4 (0.6)NRGroup X Time, p<0.0004CAPS Total - Intensity:Mean(SD)G1 Pre-tx: 2.4 (0.7)G1 3 mth FU: 0.8 (0.7)G2 Pre-tx: 2.4 (0.5)G2 3 mth FU: 2.0 (0.5)G3 Pre-tx: 2.5 (0.6)NRGroup X Time, p<0.002CAPS Total - OverallMean Change (SD) at 9 monthsG1: 36.9 (28.6)G2: 67.8 (24.7)p<0.05 | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Chard et al., 200514 | CAPS-SXG1 Pre-tx: 65.46 (26.39)G1 Post-tx: 9.00 (11.04)G2 Pre-tx 68.30 (23.67)G2 Post-tx: 62.96 (30.68)p<0.001 (interaction) | NR | NR | NR |
| Cloitre et al., 200215 | CAPSMean (SD)G1 Pre-tx:69 (16.3)G1 Post-tx: 31 (25.2)G2 Pre-tx:69 (16.6)G2 Post-tx:62 (22.7)p<.01 (interaction) | NR  | NR | NR |
| Cloitre et al., 201016 | CAPSMean (SD)G1 Pre-tx:63.08 (18.29)G1 Post-tx: 32.70 (19.37)G1 3 mth FU:24.66 (18.47)G1 6 mth FU:20.44 (19.01)G2 Pre-tx: 64.34 (21.15)G2 Post-tx: 32.32 (23.04)G2 3 mth FU:31.88 (22.98)G2 6 mth FU:32.51 (22.69)G3 Pre-tx: 64.50 (15.86)G3 Post-tx: 39.72 (18.34)G3 3 mth FU: 39.71 (17.59)G3 6 mth FU: 28.56 (21.00)Group X TimeG1 vs. G3 at 3 mths, p=0.01No other contrasts significant  | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Connor et al., 199917Meltzer-Brody et al., 200018 | NR | NR | SIPWeek 12 difference (Baseline - Endpoint) (95% CI)G1 vs. G2 Difference: 10.3 (3.7 to 16.9), p<0.005According to Meltzer-Brody paper, effect was significant for all 4 cluster scores (p<0.02) (intrusion, avoidance, numbing, hyperarousal) | Duke Global Severity Rating for PTSD (Duke)Week 12 difference (Baseline - Endpoint) (95% CI)G1 vs. G2 Difference: 1.1 (0.6 to 1.6), p<0.0001 |
| Cook et al., 201019 | CAPSMean (SD)G1 Pre-tx: 81.34 (14.00)G1 Post-tx: 74.04 (20.36)G2 Pre-tx: 79.48 (15.27)G2 Post-tx:74.85 (19.52)p<0.001 (treatment effect, Wald) | NR | NR | NR |
| Cottraux, 200820 | NR | NR | NR | NR |
| Davidson et al., 200121 | CAPS-2 Change from Baseline to Endpoint (SD)G1: -33.0 (2.4)G2: -26.2 (2.3)p=0.04 (t-test) | NR | NR | NR |
| Davidson et al., 200322 | NR | NR | SIPMean (SD)G1 Pre-tx:34.7 (7.0)G1 Post-tx:17.4 (4.0)G2 Pre-tx:38.4 (6.7)G2 Post-tx:32.9 (12.7)Between Tx effect size 1.06p=0.04 Treatment effect F=5.0; p=.04) | SPRINTMean (SD)G1 Pre-tx:21.7 (6.0)G1 Post-tx:12.4 (8.8)G2 Pre-tx:25.0 (4.2)G2 Post-tx: 19.4 (8.2)Between Tx effect size 0.49 p=NS Treatment effect, F=1.7; p=.20 |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Davidson et al., 200623 | CAPS-SX17 Mean Within-group difference (95% CI):G1: -41.51 (-45.66 to -37.36) G2: -39.44 (-43.67 to - 35.21)G3: -34.17 (-38.33 to -30.01)Between group p-values based on pairwise comparisons from the analysis of covariance model using baseline adjusted valuesG1 vs. G3: 0.015G2 vs. G3: 0.081G1 vs. G2: 0.494  | NR | NR | NR |
| Davidson et al., 200624 | CAPS-SXMean (SD)G1 Pre-tx: 81.0 (14.62)G1 Post-tx: 29.2 (26.09)G2 Pre-tx: 82.9 (15.50)G2 Post-tx: 38.1 (29.11)Between Group Mean Difference-8.9, p=0.006 | NR | NR | NR |
| Davidson et al., 200725 | CAPS Change from baseline (SD)G1: 30.7 (25.1)G2: 30.2 (26.3)p=0.85 | NR | NR | DTS & TOP-8 NR, both NS |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Davis et al., 200826 | CAPSMean(SD)G1 Pre-tx: 75.2 (19.1)G1 Post-tx: 60.1 (24.1)G2 Pre-tx: 77.3 (15.3)G2 Post-tx: 60.8 (26.6)30% reduction in PTSD scores:G1: NRG2: NRDiff b/t groups, p>0.45G1 vs. G2, diff over time, p=NS | NR | NR | TOP-8Mean(SD)G1 Pre-tx: 19.4 (5.3)G1 Post-tx: 15.4 (6.6)G2 Pre-tx: 19.7 (4.3)G2 Post-tx: 15.8 (6.5)G1 vs. G2, NS |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Ehlers et al., 200327 | CAPS Frequency Mean (SD) G1 Pre-tx: 31.7 (9.5)G1 3 mth FU: 11.2(10.3)G1 9 mth FU: 10.2 (9.9)G2 Pre-tx: 32.6 (8.6)G2 3 mth FU: 22.9 (12.9) G2 9 mth FU: 21.4 (11.4)G3 Pre-tx: 32.8 (11.5)G3 3 mth FU: 25.6 (12.9) G3 9 mth FU: 21.1 (15.2)3 mth FUOverall: p<0.001 G1 vs. G2, p<0.001 G1 vs. G3, p<0.001 9 mth FUOverall: p<0.001 G1 vs. G2: p<0.001 G1 vs. G3: p=0.001 CAPS Intensity Mean (SD) G1 Pre-tx: 26.7 (7.4)G1 3 mth FU: 10.2 (9.4) G1 9 mth FU: 9.7 (9.5)G2 Pre-tx: 26.7 (7.4)G2 3 mth FU: 19.6 (9.0) 18.6 (10.1)G2 9 mth FU: G3: 22.4 (11.9)  | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Ehlers et al., 200327(continued) | G3 Pre-tx: 25.9 (10.4)G3 3 mth FU: 22.4 (11.9)G3 9 mth FU: 17.0 (13.8)3 mth FUOverall: p <0.001 G1 vs.G2: p<0.001 G1 vs. G3: p<0.0019 mth FUOverall, p=0.002 G1 vs.G2, p=0.001 G1 vs. G3, p=0.004 |  |  |  |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Ehlers et al., 200528 | CAPS-Intensity Mean (SD)G1 Pre-tx: 36.5 (9.4)G1 Post-tx: 13.7 (13.4)G1 Post-tx FU adjusted: 10.4G1 6 mth FU: 15.5 (14.8)G2 Pre-tx: 29.0 (8.5)G2 Post-tx: 30.9 (9.6)G2 Post-tx adjusted: 34.2G1 vs. G2, p<0.005Changes in G1, p<0.005Changes in G2, NSCAPS-Frequency Mean (SD)G1 Pre-tx: 42.0 (8.5)G1 Post-tx: 16.0 (15.3)G1 Post-tx adjusted: 11.4G1 6 mth FU: 16.0 (14.4)G2 Pre-tx: 31.6 (8.4)G2 Post-tx: 35.5 (11.4)G2 Post-tx adjusted: 40.2G1 vs. G2, p<0.005Changes in G1, p<0.005Changes in G2, NS | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Fecteau et al., 199929 | CAPS-2 Mean (SD)G1 Pre-tx: 70.9 (16.2) G1 Post-tx: 37.5 (30.4) G2 Pre-tx: 77.3 (22.7) G2 Post-tx: 74.6 (24.7) Group effects, p<0.01  | NR | NR | NR |
| Foa et al., 199930Zoellner et al., 199931 | NR | PSS-IMean (SD)G1 Pre-tx: 29.48 (9.94)G1 Post-tx: 11.70 (7.32)G1 3 mth FU: 11.84 (9.01)G1 6 mth FU: 11.16 (7.38)G1 12 mth FU: 10.69 (8.96)G2 Pre-tx: 29.42 (8.69)G2 Post-tx: 12.89 (8.96)G2 3 mth FU: 15.06 (13.33)G2 6 mth FU: 11.24 (11.86)G2 12 mth FU: 12.64 (14.71)G3 Pre-tx: 29.95 (6.97)G3 Post-tx: 13.55 (9.35)G3 3 mth FU:11.45 (9.03)G3 6 mth FU: 13.17 (10.98)G3 12 mth FU: 12.56 (12.25)G4 Pre-tx 32.93 (5.89)G4 Post-tx: 26.93 (8.47)Main Effects, p<0.01G1 vs. G4, p<0.001G2 vs. G4, p<0.05G3 vs. G4, p<0.05G1 vs. G2, p=0.14G1 vs. G3, p=0.11 | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Foa et al., 200532 | NR | PSS-IMean (SD)G1 Pre-tx: 34.0 (5.9)G1 Post-tx: 17.9 (14.5)G2 Pre-tx: 31.1 (8.1)G2 Post-tx: 16.8 (13.2)G3 Pre-tx: 33.3 (6.2)G3 Post-tx: 26.8 (9.6)Group X Time interaction, p<0.01G1 vs. G3 t-test, p<0.001 | NR | NR |
| Forbes et al., 201233 | CAPSMean (SD)G1 Pre-tx: 75.53 (16.35)G1 Post-tx: 48.03 (27.89)G1 3 month FU: 45.30 (28.15)G2 Pre-tx: 64.55 (19.46)G2 Post-tx: 57.73 (20.01)G2 3 month FU: 52.55 (18.93)Change over timePost-tx, p=0.002Post vs. 3 month FU, p=0.649 | NR | NR | NR |
| Ford et al., 201134 | CAPSMean (SD)G1 Pre-tx: 62.3 (18.1)G1 Post-tx:38.7 (25.6)G2 Pre-tx: 61.9 (21.3)G2 Post-tx: 39.7 (21.4)G3 Pre-tx: 68.7 (17.0)G3 Post-tx: 62.5 (23.3)Group X Time Effect, p<0.001 | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Friedman et al., 200735 | CAPS-2Change at Endpoint (SE) G1: -13.1(3.0) G2: -15.4(3.1) Between Group Differences, NS | NR | NR | NR |
| Gamito et al., 201036 | CAPSG1 Percentage variation: -8G2 Percentage variation: -1G3 Percentage variation: -6Effects, NS | NR | NR | NR |
| Gersons et al., 200037  | NR | NR | NR | NR |
| Hamner et al., 200338  | CAPSMean (SD)G1 Pre-tx: 90.3 (23.0)G1 Post-tx: 81.3 (24.3)G2 Pre-tx: 89.1 (12.2)G2 Post-tx: 79.0 (21.0)Between-treatment changes, NS | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Hien et al., 200439  | CAPS Frequency and IntensityMean (SD)G1 Pre-tx: 72.17 (19.70)G1 Post-tx: 57.15 (22.33)G1 6 mth FU: 59.85 (21.12)G1 9 mth FU: 55.34 (20.85)G2 Pre-tx: 70.38 (16.84)G2 Post-tx: 51.21 (25.21)G2 6 mth FU: 52.65 (24.08)G2 9 mth FU: 47.82 (27.73)G3 Pre-tx: 73.88 (19.16)G3 Post-tx:68.00 (24.20)G3 6 mth FU:64.79 (23.81)G3 9 mth FU: 66.00 (23.99)CAPS Global SeverityMean (SD)G1 Pre-tx: 2.73 (0.63)G1 Post-tx: 2.14 (1.53)G1 6 mth FU:G1 9 mth FU: 1.79 (0.63)G2 Pre-tx: 2.41 (0.70)G2 Post-tx:1.75 (0.79)G2 6 mth FU: 1.62 (0.65)G2 9 mth FU: 1.40 (1.12)G3 Pre-tx: 2.82 (1.16)G3 Post-tx: 2.43 (1.09)G3 6 mth FU: 2.35 (0.70)G3 9 mth FU: 2.14 (1.07)Significance NR for CAPS | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Hien et al., 200940Hien et al., 201241 | CAPS, ITT Analysis DataMean (SD)G1 Pre-tx: 61.6 (19.4)G1 Post-tx: 31.7 (23.4)G1 Average of FU: 24.3 (22.1)G2 Pre-tx: 64.2 (19.4)G2 Post-tx.: 32.7 (23.4)G2 Average of FU: 27.1 (23.4)Post-txG1 vs. G2, p<0.001 | NR | NR | NR |
| Hinton et al., 200542 | CAPSMean (SD)G1 Pre-tx: 74.85 (14.67)G1 2nd Assessment: 39.25 (19.92)G1 3rd Assessment: 41.30 (13.95)G1 FU Assessment: 44.56 (14.58)G2 Pre-tx: 75.91 (11.5)G2 2nd Assessment: 73.05 99.43)G2 3rd Assessment: 45.05 (8.72)G2 FU Assessment: 43.56 (10.22)Group Diffferences at 2nd Assessment, p<0.001Group Differences at 1st, 3rd, & 4th assessments, NS | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Hinton et al., 200943 | CAPSMean (SD)G1 Pre-tx: 75.41 (13.47)G1 2nd Assessment: 46.83 (17.17)G1 3rd Assessment: 44.75 (14.85)G2 Pre-tx: 77.25 (11.47)G2 2nd Assessment: 74.25 (9.43)G2 3rd Assessment: 45.83 (8.45) Between group difference at 2nd assessment , p<0.01Between group differences at 3rd assessment, NS | NR | NR | NR |
| Hinton et al., 201144 | NR | NR | NR | NR |
| Hogberg et al., 200745 | NR | NR | NR | NR |
| Hollifield et al., 200746 | NR | NR | NR | NR |
| Johnson et al., 201147 | CAPS Mean (SD)G1 Pre-tx: 53.34 (24.29)G1 Post-tx: 24.76 (18.47)G1 3 mth FU: 21.15 (24.79)G1 6 mth FU: 18.62 (18.84) G2 Pre-tx: 62.69 (25.38) G2 Post-tx: 42.38 (29.33) G2 3 mth FU: 31.27 (22.01) G2 6 mth FU: 26.56 (25.83) Time effect, *p<*0 .0001Treatment effect, p>0.05 | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Krakow et al., 200148 | CAPSMean (SD) G1 Pre-tx: 81.88 (16.96)G1 Post-tx: 49.58 (23.96)Change: 32.3 (21.40)G1 Pre-tx: 79.62 (24.37)G2 Post-tx: 68.37 (27.26)Change: 11.25 (21.65)G1 vs. G2, p<0.001 | PSSMean (SD)G1 Pre-tx: 28.29 (10.37)G1 Post-tx: 17.19 (10.39)Change: 11.1 (11.06)G1 Pre-tx: 28.48 (11.73)G2 Post-tx: 25.26 (11.78)Change: 3.22 (9.02)G1 vs. G2, p<0.001 | NR | NR |
| Kruse et al., 200949 | NR | NR | NR | HTQMean (SD)G1 Pre-tx: 3.5 (0.4)G1 Post-tx: 2.2 (0.7)G2 Pre-tx: 3.5 (0.4)G2 Post-tx: 3.6 (0.3)Group X Time Interaction, p<0.001Within Group ChangeG1: p<0.001G2: p<0.05 |
| Krystal et al., 201150 | CAPSMean Difference (95 % CI)2.73 (-0.74 to 6.20)p=0.12 | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Kubany et al., 200351 | CAPS Mean (SD)G1 Pre-tx: 80.9 (20.7)G1 Post-tx: 10.1 (19.3)G1 3 mth FU: 7.9 (9.3)G2 Pre-tx: 79.1 (22.1)G2 Post-tx: 76.1 (25.2)G2 Post-therapy: 11.6 (13.6)G2 3 mth FU: 12.4 (13.8) G1 Post-tx change, p<0.05 G2 Post-tx change, NSG1 3 mth change, NSG2 Post-therapy, p<0.05G2 3 mth change, NS | NR | NR | NR |
| Kubany et al., 2004{Kubany, 2004 #806) | CAPS (ITT Sample)Mean (SD)G1 Pre-tx:74.4 (19.9)G1 Post-tx: 33.3 (32.8)G2 Pre-tx: 78.0 (20.5)G2 Post-tx: 74.1 (21.9)Between group significance, NR | NR | NR | NR |
| Liedl et al., 201153 | NR | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Lindauer et al., 200554 | NR | NR | SI-PTSD Reexperiencing ScoreMean (SD)G1 Pre-tx: 3.4 (0.9)G1 Post-tx: 1.2 (1.5)G2 Pre-tx: 3.9 (0.8)G2 Post-tx: 3.1 (1.8)G1 vs. G2, p<0.05SI-PTSD Avoidance ScoreMean (SD)G1 Pre-tx: 3.9 (1.1.)G1 Post-tx: 1.6 (2.2)G2 Pre-tx: 3.5 (0.7)G2 Post-tx: 3.2 (1.7)G1 vs. G2, NSSI-PTSD Hyperarousal Mean (SD)G1 Pre-tx: 3.8 (0.9)G2 Post-tx: 1.3 (1.8)G2 Pre-tx: 3.8 (1.0)G2 Post-tx: 2.7 (1.5)G1 vs. G2, p<0.05 | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Litz et al., 200755 | NR | PSS-IMean (SD) (Completer Group)G1 Pre-tx: 26.71 (9.02)G1 Post-tx: 14.86 (13.35)G1 3 mth FU: 13.20 (8.63)G1 6 mth FU: 8.67 (7.98)G2 Pre-tx: 29.16 (9.93)G2 Post-tx: 20.00 (11.50)G2 3 mth FU: 13.96 (8.63)G2 6 mth FU: 17.50 (10.40)ITT AnalysisPost-txTime effect, p<0.0013 mth FUG1 v.s G2, NSCompleter Analysis3 mth FUG1 vs. G2, NS6 mth FUGroup Effect, p =0.06 | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Marks et al., 199856Lovell et al., 200157 | Marks et al., 199856CAPS-2Mean Change Score at Post-tx (95% CI)G1: 30 (19 to 42) G2: 36 (26 to 45)G3: 38 (26 to 50)G4: 14 (4 to 25)Additional results presented in graphsCAPSMean change in G1 + G2 + G3 vs. G4Post, p=0.0051 mth FU, p=0.013 mth FU, p=0.005Lovell et al., 200157CAPS, Re-experiencing subscaleMean (SD)G1 Pre-tx: 13.3 (3.9)G1 Post-tx: 6.8 (7.5)G2 Pre-tx: 14.9 (5.0)G2 Post-tx: 7.8 (4.9)G3 Pre-tx: 15.1 (6.4)G3 Post-tx: 6.8 (7.2)G4 Pre-tx: 11.6 (6.1)G4 Post-tx: 9.7 (7.4)Post-txG1 + G2 +G3 vs. G4, p<0.02FollowupsG1 + G2 +G3 vs. G4, NS | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Marks et al., 199856Lovell et al., 200157cont’d | CAPS, Advoidance/numbing subscaleMean (SD)G1 Pre-tx: 23.4 (8.3)G1 Post-tx: 11.5 (13.1)G2 Pre-tx: 30.7 (7.6)G2 Post-tx: 15.2 (11.0)G3 Pre-tx: 29.8 (9.3)G3 Post-tx: 11.9 (11.9)G4 Pre-tx: 23.0 (9.1)G4 Post-tx: 17.1 (8.9)Post-txG1 + G2 +G3 vs. G4, p<0.0041 month FUG1 + G2 +G3 vs. G4, p<0.023 month FUG1 + G2 +G3 vs. G4, p<0.01CAPS, Increased arousal subscaleMean (SD)G1 Pre-tx: 25.2 (8.5)G1 Post-tx: 13.2 (11.1)G2 Pre-tx: 29.1 (8.8)G2 Post-tx: 16.5 (10.0)G3 Pre-tx: 28.6 (7.7)G3 Post-tx: 16.6 (11.7)G4 Pre-tx: 23.7 (7.6)G4 Post-tx: 17.0 (10.5)Post-txG1 + G2 +G3 vs. G4, NS |  |  |  |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Marks et al., 199856Lovell et al., 200157cont’d | FollowupsG1 + G2 +G3 vs. G4, NSCAPS, Associated features subscaleMean (SD)G1 Pre-tx: 16.7 (9.0)G1 Post-tx: 8.1 (9.7)G2 Pre-tx: 22.6 (10.2)G2 Post-tx: 10.3 (8.8)G3 Pre-tx: 20.8 (10.8)G3 Post-tx: 11.0 (11.0)G4 Pre-tx: 15.2 (8.0)G4 Post-tx: 12.0 (11.0)Post-txG1 + G2 +G3 vs. G4, p<0.04FollowupsG1 + G2 +G3 vs. G4, NS |  |  |  |
| Marshall et al., 200158 | CAPS-2Adjusted Mean Differences (95% CI)G1 vs. G3-14.3 (-19.7 to -8.8)p<0.001G2 vs. G3-12.2 (-17.7 to -6.6)p<0.001 | NR | NR | TOP-8Adjusted Mean Differences (95% CI)G1 vs. G3-3.4 (-5.1 to -1.8)p<0.001G2 vs. G3-2.9 (-4.5 to -1.3)p<0.001 |
| Martenyi et al., 200259Martenyi et al., 200660 | CAPSChanges from Pre-tx to Post-txLeast Square Means (SD), p-valueG1: -34.6 (28.1)G2: -26.8 (26.1)p=0.021 | NR | NR | TOP-8 Changes from Pre-tx to Post-txLeast Square Means, p-valueG1: -10.3G2: -8.0p=0.006 |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Martenyi et al., 200761 | CAPS Mean change from baseline (SD) ITT AnalysisG1: -42.9 (23.1)G2: -42.8 (27.9)G3: -36.6 (25.7) Overall p-value= 0.15 | NR | NR | TOP-8 Mean change from baseline (SE)Completer analysisG1: -10.59 (0.58)G2: -10.25 (0.60)G3: -10.59 (0.81)Overall p-value= 0.907 |
| McDonagh et al., 200562 | CAPSMean (SD)G1 Pre-tx: 69.9 (16.8)G1 Post-tx: 53.1 (28.8)G2 Pre-tx: 67.7 (14.6)G2 Post-tx: 47.2 (22.4)G3 Pre-tx: 72.0 (17.6)G3 Post-tx: 65.5 (18.6)Group X Time, p<0.10 | NR | NR | NR |
| Monnelly et al., 200363 | NR | NR | NR | NR |
| Monson et al., 200664 | CAPSMean (SE)G1 Pre-tx: 76.73 (2.6)G1 Post-tx: 52.14 (3.9)G1 1 mth FU: 58.13 (4.5)G2 Pre-tx: 79.10 (3.5)G2 Post-tx: 76.03 (3.7)G1 1 mth FU: 74.37 (4.3)Group X Time, p<0.01 | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Mueser et al., 200865 | CAPS Mean (SD)G1 Pre-tx: 74.46 (17.56)G1 Post-tx: 55.53 (27.92)G1 3 mth FU: 55.10 (25.96)G1 6 mth FU: 57.48 (25.34)G2 Pre-tx: 76.15 (17.07)G2 Post-tx: 67.78 (26.84)G2 3 mth FU: 64.80 (28.25)G2 6 mth FU: 70.90 (24.15)Group effect, p=0.005 | NR | NR | NR |
| Nacasch et al., 201166 | NR | PSS-IMean (SD)G1 Pre-tx: 37.1 (3.8)G1 Post-tx: 18.9 (9.1)G1 FU: 16.3 (10.4)G2 Pre-tx: 36.8 (6.2)G2 Post-tx: 35.0 (8.9)G2 FU: 35.4 (7.6)Post-txTreatment X Time, p<0.00112 month FUTreatment X Time (Pre to FU), p<0.001Treatment X Time (Post to FU), NS | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Neuner et al., 200467 | NR | NR | NR | Composite International Diagnostic Interview-PTSDMean (SD)G1 Pre-tx: 13.4 (2.1)G1 1 year FU: 8.9 (2.7)G2 Pre-tx: 13.9 (2.3)G2 1 year FU: 12.6 (3.2)G3 Pre-tx: 14.2 (2.9)G3 1 year FU: 13.4 (3.3)1 year Group X TimeG1 vs. G2, p=0.01G1 vs. G3, p=0.01 |
| Neuner et al., 200868 | NR | NR | NR | PDSMean (SD)G1 Pre-tx: 25.9 (13.2)G1 Post-tx: 5.4 (6.6)G1 6 mth FU: 6.1 (6.8)G2 Pre-tx: 26.7 (12.5)G2 Post-tx: 5.3 (5.7)G2 6 mth FU: 5.0 (6.6)G3 Pre-tx: 21.3 (10.6)G3 Post-tx: NRG3 6 mth FU: 10.1 (8.1)G1 vs. G2 ComparisonsGroup X Time at Post-tx, p=0.87Treatment Groups vs. ControlTreatment X Time, p=0.01 |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Neuner et al., 201069 | NR | NR | NR | PDSMean(SD)G1 Pre-tx: 38.9 (6.4)G1 Post-tx: 26.0 (9.2)G2 Pre-tx: 36.9 (8.0)G2 Post-tx: 34.1 (6.1)Group X Time, p=0.01 |
| Nijdam et al., 201270 | NR | NR | SI-PTSDMean Difference at 1st Post (95% CI)10.80 (6.37 to 15.23)p<0.001Mean Difference at 2nd Post (95% CI)2.41 (-2.10 to 6.92)p=0.29 | NR |
| Panahi et al., 201171 | NR | NR | NR | NR |
| Petrakis et al., 201172 | CAPSMean( SE)G1 Pre-tx: 73.54 (5.007)G1 Post-tx: 40.024 (5.53)G2 Pre-tx: 69.810 (5.166)G2 Post-tx: 36.591 (5.570)G3 Pre-tx: 62.500 (5.047)G3 Post-tx: 26.751 (5.353)G4 Pre-tx: 77.833 (4.832)G4 Post-tx: 41.392 (4.949)Time effect, p<0.00Group X Time, NS | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Raskind et al., 200373 | CAPS G1 Pre-tx:79.1 (17.0)G1 Post-tx: 57.3 (32.3)G2 Pre-tx: 83.6 (17.6)G2 Post-tx: 86.5 (30.0)G1 vs. G2 Change, p<0.01 | NR | NR | NR |
| Raskind et al., 200774 | CAPSMeans (SD)G1 Pre-tx: 76.0 (22)G1 Post-tx: 63.0 (20.0)G2 Pre-tx: 78.0 (18.0)G2 Post-tx: 71.0 (22.0)G1 vs. G2 Change, NS | NR | NR | NR |
| Reich et al., 200475 | CAPS-2Mean Changes from Baseline Score (SD)G1: -29.6 (31.5)G2: -18.6 (12.3)p=0.015 | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Resick et al., 200276Resick et al., 200377Resick et al., 201278 | CAPSMean (SD)G1 Pre-tx: 74.76 (18.77)G1 Post-tx: 39.08 (31.12)G1 3 mth FU: 42.21 (30.13G1 9 mth FU: 42.87 (31.06)G1 LTFU: 26.00 (23.35)G2 Pre-tx:76.60 (19.72)G2 Post-tx: 44.89 (33.52)G2 3 mth FU: 49.16 (32.86) G2 9 mth FU: 46.98 (33.68)G2 LTFU: 25.90 (26.05)G3 Pre-tx: 69.85 (19.57)G3 Post-tx: 69.26 (18.55)G3 3 mth FU: 69.26 (18.55)G3 9 mth FU: 69.26 (18.55)Posttreatment differences, p<.0001 3 mth FU differences, p<0.0001 9 mth FU differences, p<0.0001LTFU differences, NS | NR | NR | NR |
| Rothbaum et al., 199779 | NR | PSSMean (SD)G1 Pre-tx: 33.3 (8.7)G1 Post-tx: 14.3 (8.4)G1 3 mth FU: 9.8 (8.7)G2 Pre-tx: 39.0 (8.2)G2 Post-tx: 35.0 (5.9)Posttreatment G1 vs. G2, p<0.05 | NR | NR |
| Rothbaum et al., 200580 | Data reported in graphs | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Rothbaum et al., 200681 | NR | NR | SIPMean Change from Baseline (SD)G1: -0.3 (7.60) p=nsG2: 5.9 (7.82)p<0.001G1 vs. G2, ns (t-test) | NR |
| Schneier et al., 201282 | CAPS Mean (SD)G1 Pre-tx: 72.6 (12.9)G1 Post-tx: 21.5 (19.9)G2 Pre-tx: 65.4 (12.8)G2 Post-tx: 35.6 (31.3)Treatment Group Effect, p=0.01Time Effect, p<0.001 | NR | NR | NR |
| Schnurr et al., 200383 | CAPS Mean (SE)G1 Pre-tx: 80.41 (1.45)G1 7 mth FU: 74.00 (1.32)G1 12 mth FU: 72.79 (1.51)Change at 7 mths, p<0.001Change at 12 mths, p<0.001G2 Pre-tx: 82.01 (1.44)G2 7 mth FU: 76.03 (1.32)G2 12 mth: 74.82 (1.49)Change at 7 mths, p<0.001Change at 12 mths, p<0.001Treatment Effect, p=0.29Cohort Effect, p=0.01Treatment X Cohort Effect, p=0.04 | NR | NR | PTSD ChecklistMean (SD)G1 Pre-tx: 61.84 (0.91)G1 7 mth FU: 59.70 (0.84)G1 12 mth FU: 58.78 (0.89)Change at 7 mths, p<0.01Change at 12 mths, p<0.01G2 Pre-tx: 62.60 (0.94)G2 7 mth FU: 61.03 (0.84)G2 12 mth FU: 60.00 (0.88)Change at 7 mths, p>0.05Change at 12 mths, p<0.05Treatment Effect, NSTreatment X Cohort Effect, p=0.05 |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Schnurr et al., 200784 | CAPSBaselineMean (95% CI)G1: 77.6 (74.8 to 80.4)G2: 77.9 (75.1 to 80.6)Least Means (95% CI)Immediate posttreatment G1: 52.9 (47.7 to 58.0) G2: 60.1 (55.3 to 64.8) G1 vs. G2, *P*=.013 mth FUG1: 49.7 (44.7 to 54.7) G2: 56.0 (50.5 to 61.5) G1 vs. G2, *P*=.0476-monthG1: 50.4 (45.0 to 55.8) G2: 54.5 (49.3 to 59.7) G1 vs. G2, p =.21Treatment Effect, p=0.03Treatment X Time, p=0.37 | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Schnyder et al., 201185 | CAPS Mean (SD)G1 Pre-tx: 78.6 (16.0)G1 Post-tx: 60.8 (32.8)G1 6 mth FU: 58.1 (30.5)G2 Pre-tx: 73.4 (19.2)G2 Post-tx: 66.4 (20.0)Group Effect, p<0.01 | NR | NR | NR |
| Simon et al., 200886 | NR | NR | NR | SPRINTMean (SD)G1 Pre-tx: 16.11 (8.99)G1 Improvement Post-tx: 2.33 (5.24)G2 Pre-tx: 17.00 (7.65)G2 Improvement Post-tx:4.57 (7.24) p=NS |
| Spence et al., 201187 | NR | NR | NR | NR |
| Stein et al., 200288 | CAPSMean Change from Baseline (95% CI)G1: -14.8 (SD=14.16)p<.05 G2 : -2.67 (SD=10.55)p<0.05 | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Tarrier et al., 199989Tarrier et al., 199990 | CAPS Global SeverityMean (SD)G1 Pre-tx: 71.14 (18.98)G1 Post-tx: 48.24 (30.25)G1 6 mth FU: 52.11 (23.78)G2 Pre-tx: 77.76 (14.95)G2 Post-tx: 50.82 (23.99)G2 6 mth FU: 50.21 (24.37)G1 vs. G2 differences, NS12-Month Follow-upG1 Pre-tx: 71.76 (19.59)G1 12 mth FU: 45.16 (28.26)G2 Pre-tx:76.93 (15.40)G2 12 mth FU: 52.48 (24.09)G1 vs. G2 differences, NS | NR | NR | NR |
| Taylor et al., 200391 | CAPSData only reported in graphsCompletersG1 Pre-Post changes, p<0.005G2 Pre-Post changes, p<.001G3 Pre-Post changes, p<0.005Intent to TreatNo significant differences | NR | NR | NR |
| Tucker et al., 200192 | CAPS-2Adjusted Mean Differences (95% CI), G1 vs. G2-10.6 (-16.2 to -5.0) | NR | NR |  TOP-8Adjusted Mean Differences (95% CI), G1 vs. G2-3.8 (-5.6 to -1.9) |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Tucker et al., 200393Tucker et al., 200494 | Tucker et al., 2004CAPSMean (SD)G1 Pre-tx: 91.0 (10.58)G1 Post-tx: 60.28 (26.15)G2 Pre-tx: 83.91 (17.28)G2 Post-tx: 42.09 (29.09)G3 Pre-tx: 94.20 (11.9)G3 Post-tx: 55.5 (29.07)Between group differences, NS | NR | NR | NR |
| Tucker et al., 200795 | CAPSMean Percentage Change (SD)G1: -59.5 (35.9)G2: -45.5 (34.3)p=0.227  |  NR | NR | TOP-8Mean Percentage Change (SD)G1: -67.9 (30.0) G2: -41.6 (37.8)p= 0.023 |
| van der Kolk et al., 199496 | CAPSDifference in Improvement G1 vs. G2= 12.59ANCOVA ResultsF = -12.59, t = -2.67, p=0.0106 | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| van der Kolk et al., 200797 | CAPS Mean (SD) ( Post-tx & FU - ITT)G1 Pre-tx (1 mth CAPS): 71.7 (11.9)G1 Pre-tx (1 wk CAPS): 69.4 (12.7)G1 Post-tx: 32.55 (22.5)G1 FU: 25.79 (21.61)G2 Pre-tx (1 mth CAPS): 75.9 (15.6)G2 Pre-tx (1 wk CAPS): 73.7 (13.4)G2 Post-tx: 42.67 (22.11)G2 FU: 42.12 (15.83)G3 Pre-tx (1 mth CAPS): 74.5 (12.5)G3 Pre-tx (1 wk CAPS): 70.3 (13.0)G3 Post-tx: 43.55 (22.6)G3 FU: NAPosttreatmentTreatment effect, NSG1 vs. G3, NSG2 vs G3, NSG1 vs. G2, NSFollowupG1 vs. G2, p=0.005 |   |   |   |
| van Emmerik et al., 200898 | NR | NR | NR | NR |
| Yeh et al., 201199 | CAPSMean( SD)G1 Pre-tx: 78.76 (12.64)G1 Post-tx: 30.41 (30.90)G2 Pre-tx: 66.14 (22.63)G2 Post-tx: 35.78 (33.76)Between Group Change, p=0.49  | NR | NR | NR |

Table D-4. Clinician administered PTSD scales (continued)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Author, Year | Clinician Administered CAPS or CAPS 2 | Clinician Administered PSS-I | Clinician Administered SI-PTSD | Clinician Administered Other |
| Zlotnick et al., 2009100 | CAPS Mean difference (95% CI)-2.30 (-13.81, 9.21) | NR | NR | NR |
| Zohar et al., 2002101 | CAPS-2Mean Change from Baseline (SD) G1: -18.7 (6.7)G2: -13.5 (6.6)Between Group Change, p=0.530 | NR | NR | NR |

Abbreviations: ANOVA = analysis of variance; ANCOVA = analysis of covariance; CAPS = Clinician-administered PTSD Scale; CI = confidence interval; FU = follow-up; NR= not reported; NS = not significant; PSS= PTSD Symptom Scale; PSS-I= PTSD Symptom Scale Interview; Pre-tx = pretreatment; Post-tx = Posttreatment; PTSD= Post-Traumatic Stress Disorder; SD = standard deviation; SE = standard error; SI-PTSD or SIP= Structured Interview for PTSD; SPRINT=  Short PTSD Rating Interview; TOP-8 = Treatment Outcome PTSD Scale; SD = standard deviation; SE = standard error.